Mechanism of Action
RYBREVANT® is a bispecific antibody that binds to the extracellular domains of EGFR and MET and disrupts EGFR and MET signaling functions through1:
- Blocking ligand binding, and degradation of EGFR and MET1
- Antibody-dependent cellular cytotoxicity and trogocytosis1
See how RYBREVANT® works
Watch this video about the MOA of RYBREVANT®, engineered to take on EGFR exon 20 insertion mutations1
EGFR, epidermal growth factor receptor; MET, Mesenchymal-Epithelial Transition.
1. RYBREVANT® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.